Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“ADCs for non-oncology indications?
Preclinical paper describing the discovery, optimization, and development of AMG 133 out on ACS Publications Bio and Med Chem Content.
AMG 133 (maridebart cafraglutide) = anti-GIPR-Ab conjugated to a synthetic GLP-1 peptide!”
Title: Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity
Authors: Bin Wu, James R. Falsey, Chawita Netirojjanakul, Brad Herberich, Jerry Ryan Holder, Kelvin Sham, Jennifer Aral, Neil Forsythe, Kenneth W. Walker, Shu-Chen Lu, Todd Hager, Shanaka Stanislaus, Renee Komorowski, Larissa Atangan, Michal Achmatowicz, Dante Romanini, Dohan Weeraratne, Les P. Miranda, Murielle M. Véniant, Yuan Cheng
Read the full article on ACS Publications.
Other articles featuring Raffaele Colombo on OncoDaily.